Please provide your email address to receive an email when new articles are posted on . Cobenfy is the first antipsychotic medication to treat schizophrenia by targeting cholinergic receptors. The ...
In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the ...
New M1 orthosteric agonist protects against scopolamine-induced damage in in vitro Alzheimer’s disease model Dec. 27, 2024 ...
The US Food and Drug Administration (FDA) has approved Cobenfy (Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia. The drug targets cholinergic receptors as opposed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback